U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT06897605) titled 'Dapagliflozin Use in Anemic Patients with Chronic Kidney Disease' on March 20.

Brief Summary: Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor. Primarily, it is indicated for the management of type 2 diabetes mellitus. Emerging research has suggested that SGLT2 inhibitors may confer additional benefits by attenuating the risk of adverse cardiovascular events and renal complications. Subsequent post hoc analyses of previous clinical trials have indicated that patients administered with SGLT2 inhibitors, exhibited increased levels of hemoglobin and hematocrit compared to those in the control group. These findings ...